NanoVibronix Inc. has published a letter to shareholders outlining a new strategic direction and plans for rebranding. The company intends to change its name to ENvue Medical and adopt a new NASDAQ ticker symbol. A review of operations and technologies identified the ENvue Feeding Tube Placement System as the core growth platform. NanoVibronix Inc. is also considering strategic alternatives for legacy assets, such as partnerships or divestitures. Additional updates regarding the Board of Directors, leadership team, and clinical progress are expected following the Annual Meeting on December 4, 2025. The full letter can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoVibronix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-024167), on November 19, 2025, and is solely responsible for the information contained therein.